Aug 2026· Current Opinion in Cardiology· Vol 41, pp. 593-599· 0 citations· 22 references
Medicine
TL;DR
For patients with AF after ACS or PCI, DOAC-based dual antithrombotic therapy provides the most favorable cumulative safety-efficacy balance, and future research should focus on the timing of aspirin discontinuation and validate recurrent-event endpoints.
Abstract
Purpose
OF REVIEW
Antithrombotic therapy for patients with atrial fibrillation (AF) after acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) requires balancing prevention of stroke and coronary events against bleeding. Recent recurrent-event and patient-centered analyses of AUGUSTUS make this review timely by reframing treatment benefit beyond first events.
RECENT
Findings
Four dedicated trials support dual antithrombotic therapy with direct oral anticoagulants (DOAC) plus P2Y12 inhibitor and early aspirin withdrawal to reduce bleeding without significant increase in ischemic events. However, aspirin-free strategies differ by anticoagulation indication: in patients without anticoagulation, very early aspirin withdrawal after ACS or PCI may increase the risk of coronary events, whereas in patients with AF receiving anticoagulation, oral anticoagulation may assume the early antithrombotic role of aspirin. AUGUSTUS showed that apixaban and placebo each reduced bleeding compared with vitamin K antagonist and aspirin. The recent total-event analyses further showed lower cumulative bleeding with apixaban than with vitamin K antagonist, and substantially greater cumulative bleeding with randomized aspirin than with placebo, along with similar total ischemic events and hospitalizations.
SUMMARY
For patients with AF after ACS or PCI, DOAC-based dual antithrombotic therapy provides the most favorable cumulative safety-efficacy balance. Future research should focus on the timing of aspirin discontinuation and validate recurrent-event endpoints.
Antithrombotic therapy management in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains challenging as it requires simultaneous protection from cardioembolism and coronary ischemic events while minimizing bleeding. The coexistence of these competing risks, along with thei...
Carmelo Raffo, D. Giacoppo, D. Capodanno et al.· Journal of Clinical Medicine· 0 citations
ADONIS-PCI is among the first randomized evaluations of a reduced-dose long-term ticagrelor strategy combined with dabigatran in patients with AF and ACS undergoing PCI, addressing an important evidence gap in the selection and dosing of P2Y12 inhibition when aspirin is discontinued early in this high-risk population.
M. Jaguszewski, Aleksandra Gąsecka-van der Pol, N. Gilis-Malinowska et al.· Cardiology Journal· 0 citations
A patient-level meta-analysis of randomized trials evaluating antithrombotic strategies in patients with AF undergoing PCI found the risk of cardiovascular death, myocardial infarction, or stroke did not significantly differ according to whether patients received a DOAC or VKA, whereas a modest increase in risk with si...
M. Chiarito, R. Mehran, Michael C. Gibson et al.· European Heart Journal· 0 citations
Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications, and these findings do not support the routine use of potent P2Y12 inhibitors in combination with DOACs in this patient population.
Konstantinos D. Rizas, K. Mourouzis, D. Rath et al.· Nature Medicine· 3 citations
Current evidence suggests that indobufen-based DAPT may provide comparable ischemic protection with fewer bleeding or gastrointestinal adverse events in selected PCI patients, particularly those with aspirin intolerance, gastrointestinal vulnerability, or high bleeding risk.
Jia-Hui Chai, Xue-Bo Li, Qian Liu et al.· Cardiology in Review· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.